A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 766 participants.

Also called NCT04161430

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 766 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04161430
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04161430. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-02 (actual); primary completion 2022-06-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of DBPR108 100 mg in Type 2 Diabetes Mellitus Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
DBPR108; Placebo matching sitagliptin
Intervention (Drug)
Placebo matching DBPR108; Sitagliptin; DBPR108
Intervention (Drug)
Placebo matching DBPR108; Placebo matching sitagliptin; DBPR108
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04161430
Content hash
a0d2ef27cdc074dafc37e7a833ca6f71edc44842503c3e72eb0d177a6012722b